The COVID-19 pandemic has created many challenges for our clinical and scientific communities. Here we share COVID-19-related resources we hope will assist our community in continuing to support all people living with MS.
Please remember, we’re all in this together!
- Covid-19 Meetings
- Latest updates from Twitter #MSCOVID19
- Clinical Perspectives
- MS COVID Registries
- Scientific Perspectives & Impacts
- Information for people living with MS
- Contact Us
iWiMS COVID-19 Meetings
Join a bi-weekly COVID-19 Discussion – timing will change to accomodate different time zones, so please keep an eye on this.
Our next call will be on Wednesday August 26th more details to follow
The link to our next ZOOM meeting is here
The recordings from our previous MS COVID-19 meetings can be found here.
Podcasts of our sessions are also available for download.
The #MSCOVID19 Twitter hashtag was created by @drbarrysinger to share clinical experiences of people with MS who have contracted COVID-19. Follow this tag to discover how people with MS on varying disease-modifying therapies have responded to this virus.
So far a lot of good news stories!
Here we will share links to blogs and other resources as we come across them, sharing clinical perspectives on MS management in the context of COVID-19.
The latest paper from MSARD addressing “The COVID-19 pandemic and the use of MS Disease-Modifying Therapies” can be found here
The Association of British Neurologists (ABN) has posted some guidelines on COVID-19 and MS, and COVID-19 and neurological conditions. Information can be found here.
In Neurology Today Dr Orly Avitzur, President of the AAN writes of the disruptions to clinical practice and research as a result of COVID-19, and experiences of clinicians and scientists working in our field.
New TOCOVID-19; Tocilizumab in COVID-19 Pneumonia trial has commenced. Information can be found here.
FacebookLive event held by MSTranslate in Australia. Here clinicians from the Royal Melbourne Hospital discuss the impact of COVID-19 on people with MS, and treatment decision strategies.
Stopping the spread of COVID-19 – Patient Resource from JAMA published 20 March 2020
MS COVID Registries
COViMS is a new North American Registry capturing cases of COVID-19 in MS patients. A collaboration between the NMSS and the CMSC.
The Registry can be accessed here
LEOSS: A new Register of SARS-CoV-2 in European Patients. More information can be found at this website.
The Multiple Sclerosis International Federation (MSIF) and the Multiple Sclerosis Data Alliance (MSDA) recently teamed up for a joint Global Data Sharing Initiative. Details of this register can be found here.
MuSC-19 Italian MS COVID-19 Registry – no website available, but the CRF can be found here
There is also a new Italian effort to collate cases of SARS-CoV-2 in people with MS. This, and other registry efforts will be discussed during our call on 1st April.
Scientific Perspectives and Impacts
Serological Testing for SARS-CoV-2
Learn more about the serological COVID-19 testing program that Dr Michael Wilson spoke about at our meeting on 29 April, please visit the COVID-19 Testing Project page here
The NIH is posting guidance for applicants and grantees relating to award
management, clinical trials, and more.
Information for NIH Applicants and Recipients of NIH Funding
A preliminary report published on BioRxiv by a reputable team can be found here.
Information resource for people living with MS
Some additional excellent resources for people with MS can be found at the MS International Federation (MSIF) page here.
We thank the NMSS for sharing their patient resources with us.
The National MS Society is posting and updating information regularly to help people living with MS to navigate this crisis:
What You Need To Know About Coronavirus (COVID-19)
This page links to specific guidance on DMTs:
Disease Modifying Treatment Guidelines for Coronavirus (COVID-19)
The Society also has posted a blog to help people manage their MS:
Check List: Managing MS Through the COVID-19 Crisis
If you have any further information you would like us to consider adding here. Please contact us. firstname.lastname@example.org